Real‐World Cardiovascular Outcomes of <scp>GLP</scp> ‐1 Receptor Agonists in Women With Type 2 Diabetes and Breast Cancer
This study demonstrated the potential CV benefit of GLP-1 RA therapies among a population of female breast cancer survivors with T2D. Randomized trial data are needed to confirm these findings.
Authors
- Aimon C. Miranda (ORCID: https://orcid.org/0000-0003-1683-3982)
- Cyrille K. Cornelio (ORCID: https://orcid.org/0000-0003-0499-675X)
- Raechel T. White (ORCID: https://orcid.org/0000-0002-5929-5590)
- Janelle Perkins (ORCID: https://orcid.org/0000-0002-5681-9061)
- Ricardo Pineda Gayoso
- Anh T. Phan
- Mohammed E. Alomar
- Kevin Cowart
Institutions
- University of South Florida (US)
- University of Michigan (US)
- Moffitt Cancer Center (US)
- Michigan Medicine (US)
Publication Details
- Journal
- Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy
- Published
- 2026-03-09
- DOI
- https://doi.org/10.1002/phar.70130
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00